Anti-Cd30 Antibody Conjugated Liposomal Doxorubicin With Significantly Improved Therapeutic Efficacy Against Anaplastic Large Cell Lymphoma

Biomaterials - United Kingdom
doi 10.1016/j.biomaterials.2013.07.068
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Course of Anti-Alk Antibody Titres During Chemotherapy in Children With Anaplastic Large Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma. A Series of Nine Cases

Gaceta Medica de Mexico
Medicine
2019English

Ki-1 (CD30)-positive Anaplastic Large Cell Lymphoma, Sarcomatoid Variant Accompanied by Spontaneously Regressing Lymphadenopathy.

Internal Medicine
Internal MedicineMedicine
1999English

Anaplastic Large Cell Lymphoma Presenting With Paraneoplastic Pemphigus

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2007English

Primary Cutaneous Anaplastic Large Cell Lymphoma

Journal of Cutaneous Pathology
DermatologyForensic MedicinePathologyHistology
2017English

ALK-negative Anaplastic Large Cell Lymphoma

2020English

Breast Implant-Associated Anaplastic Large Cell Lymphoma vs. Anaplastic Large Cell Lymphoma in a Patient With Breast Implant Effusion History: A Diagnostic Dilemma

Journal of Hematopathology
Forensic MedicinePathologyHematologyHistology
2016English

CD30-targeted Oncolytic Viruses as Novel Therapeutic Approach Against Classical Hodgkin Lymphoma

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy